Specific vaccine therapy in chronic hepatitis B: Induction of T cell proliferative responses specific for envelope antigens

Journal of Infectious Diseases

Volumn 180, Issue 1, 1999, Pages 15-26

  Couillin, I ^a   Pol, S ^b   Mancini, M ^a   Driss, F ^c   Brechot C ^b   Tiollais, P ^a   Michel, M L ^a  

^a INSTITUT PASTEUR   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; VIRUS ENVELOPE PROTEIN;

ANTIGEN RECOGNITION; ARTICLE; CELLULAR IMMUNITY; CHRONIC HEPATITIS; CONTROLLED STUDY; HELPER CELL; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VACCINATION; VIRUS ENVELOPE;

EPITOPES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; LYMPHOCYTE ACTIVATION; PILOT PROJECTS; T-LYMPHOCYTES; TH1 CELLS; VACCINATION; VACCINES, SYNTHETIC; VIRUS REPLICATION;

EID: 0033050827     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314828     Document Type: Article

References (44)

1. Chisari FV. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
2. Maruyama T, McLachlan A, Lino S, Koike K, Kurokawa K, Milich DR. The serology of chronic hepatitis B infection revisited. J Clin Invest 1993;91:2586-95.
3. Chisari FV. Immunobiology and pathogenesis of viral hepatitis. In: Rizzetto M, Purcell RH, Gerin JL, Verme G, eds. Viral hepatitis and liver disease. Turin, Italy: Edizioni Minerva Medica, 1996:405-14.
4. Celis E, Kung PC, Chang TW. Hepatitis B virus reactive human T lymphocytes clones: antigen specificity and helper function for antibody synthesis. J Immunol 1984;132:1511-6.
5. Celis E, Ou D, Otvos L Jr. Recognition of hepatitis B surface antigen by human T lymphocytes. Proliferative and cytotoxic responses to a major antigenic determinant defined by synthetic peptide. J Immunol 1988;140:1808-15.
6. Jin Y, Shih JWK, Berkowe I. Human T cell response to the surface antigen of hepatitis B virus (HBsAg): endosomal and nonendosomal processing pathways are accessible to both endogenous and exogenous antigen. J Exp Med 1988;168:293-306.
7. Ferrari C, Penna A, Bertoletti A, et al. The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man. J Clin Invest 1989;84:1314-9.
8. Wright TL, Lau JYN. Clinical aspects of hepatitis B virus infection. Lancet 1993;342:1340-4.
9. Zoulim F, Trépo C. Virus de l'hépatite B: replication et mécanismes d'action des antiviraux. Virologie 1997;3:197-15.
10. Mancini M, Hadehouel M, Tiollais P, Pourcel C, Michel ML. Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg transgenic mice: a possible way of circumventing "nonresponse" to HBsAg. J Med Virol 1993;39:67-74.
11. Mancini M, Hadehouel M, Davis HL, Whalen RG, Tiollais P, Michel ML. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci USA 1996;93:12496-501.
12. Pol S, Driss F, Carnot F, Michel ML, Berthelot P, Brechot C. Vaccination against hepatitis B virus: an efficient immunotherapy against hepatitis B multiplication. C R Acad Sci III 1993;316:688-91.
13. Pol S, Driss F, Michel ML, Nalpas B, Berthelot P, Brechot C. Specific vaccine therapy in chronic hepatitis B infection [letter]. Lancet 1994;344:342.
14. Barlet V, Cohard M, Thelu MA, et al. Quantitative detection of hepatitis B virus DNA in serum using chemiluminescence: comparison with radio-active solution hybridization assay. J Virol Methods 1994;49:141-51.
15. Michel ML, Pontisso P, Sobczak E, Malpiece Y, Streeck RE, Tiollais P. Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin. Proc Natl Acad Sci USA 1984;81:7708-12.
16. Ellis RW, Kniskern PJ, Hagopian A, et al. Preparation and testing of a recombinant-derived hepatitis B vaccine consisting of Pre-S2 + S polypeptides In: Zuckerman AJ, ed. Viral hepatitis and liver disease. New York: Alan R Liss, 1988:1079-86.
17. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1992;298:347-50.
18. Pasek M, Goto T, Gilbert W, et al. Hepatitis B virus gene and their expression in Escherichia coli. Nature 1979;282:575-9.
19. Neurath AR, Kent SBH, Strick N, Taylor P, Stevens CE. Hepatitis B virus contains pre-S gene-encoded domains. Nature 1985;351:154-6.
20. Vingerhoets J, Vanham G, Kestens L, Penne G, Leroux-Roels G, Gigase P. Deficient T-cell responses in non-responders to hepatitis B vaccination: absence of TH1 cytokine production. Immunol Lett 1994;39:163-8.
21. Jin Y, Shih WK, Alter HJ, Berkower I. An oligoclonal human T-cell line specific for HBsAg is restricted to MHC class I antigens and responds to soluble antigen and to endogenous HBsAg. In: Zuckerman AJ, ed. Viral hepatitis and liver disease. New York: Alan R Liss, 1988:678-83.
22. Leroux-Roels G, Desombere I, De Tollenaere G, et al. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. I. Safety and immunogenicity in young, healthy adult. Vaccine 1997;15:1724-31.
23. Deulofeut H, Iglesias A, Mikael N, et al. Cellular recognition and HLA restriction of a midsequence HBsAg peptide in hepatitis B vaccinated individuals. Mol Immumol 1993;30:941-8.
24. Egea E, Iglesias A, Salazar M, et al. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med 1991;173:531-8.
25. Desombere I, Hauser P, Rossau R, Paradijs J, Leroux-Roels G. Nonresponders to hepatitis B vaccine can present envelope particles to T lymphocytes. J Immunol 1995;154:520-9.
26. Milich DR, McLachlan A, Chisari FV, Kent SB, Thornton GB. Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1) specific T cell response can bypass nonresponsiveness to the pre S(2) and S regions of HBsAg. J Immunol 1986;137:315-22.
27. Ip CC, Miller WJ, Kubek DJ, et al. Structural characterization of the N-glycans of a recombinant hepatitis B surface antigen derived from yeast. Biochemistry 1992;31:285-95.
28. Michaëlsson E, Malmström V, Reis S, Engström A, Burkhardt H, Holmdahl R. T cell recognition of carbohydrates on type II collagen. J Exp Med 1994;180:745-9.
29. Haurum JS, Arsequell G, Lellouch AC, et al. Recognition of carbohydrate by major histocompatibility complex class I restricted, glycopeptide-specific cytotoxic T lymphocytes. J Exp Med 1994;180:739-44.
30. Botarelli P, Houlden BA, Haigwood NL, Servis C, Montagna D, Abrignani S. N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes. J Immunol 1991;147:3128-323.
31. Diminsky D, Schirmbeck R, Reiman J, Barenholz Y. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine 1997;15:637-47.
32. Lanzavecchia A. Mechanism of antigen uptake for presentation. Curr Opin Immunol 1996;8:348-54.
33. Guidotti LG, Ando K, Hobbs MV, et al. Cytotoxic T lmphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994;91:3764-8.
34. Peters M. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology 1996;23:909-16.
35. Alberti A, Cavaletto D, Pontisso P, Chemello L, Tagarielllo G, Belussi F. Antibody response to pre-S2 and hepatitis B virus induced liver damage. Lancet 1988;331:1421-4.
36. Budkowska A, Dubreuil P, Poynard T, et al. Anti-pre-S responses and viral clearance in chronic hepatitis B virus infection. Hepatology 1992;15:26-31.
37. + T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol 1995;69:3358-68.
38. Tsai SL, Chen PJ, Lai MY, et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. J Clin Invest 1992;89:87-96.
39. Marinos G, Torre F, Chokshi S, et al. Induction of T-helper cell response to hepatitis B core antigen in chronic hepatitis B: a major factor in activation of the host immune response to the hepatitis B virus. Hepatology 1995;22:1040-9.
40. + antibodies and restored specific T cell proliferation in vivo in a patient with chronic hepatitis C. J Immunol 1997;159:4064-71.
41. + T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. J Virol 1997;71:2241-51.
42. + T cell responses associated with control of viremia. Science 1997;278:1447-50.
43. + cytotoxic T-cell responses during chronic viral infection. J Virol 1994;68:8056-63.
44. + T cells. Curr Opin Immunol 1998;10:444-9.